Related Articles
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review).
Cost-effectiveness of neoadjuvant multimodal therapy in patients with esophageal adenocarcinoma
Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R
Cost‑effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma